Home|Journals|Articles by Year|Audio Abstracts RSS - TOC

SJEMed. 2022; 3(2): 166-170

A case of SVT: response to the third dose of Adenosine

Amal Yousif, Ali Mohammed Aljabri, Monther Alshahrani.


Background: Supraventricular tachycardia (SVT), manifested as rapid and regular heartbeat, is the most frequent symptomatic tachyarrhythmia requiring medical intervention in children. SVT occurs in 1 in every 250-1,000 children. The heart rate can be as high as 180 beats/minute in children and 220 beats/minute in Infants. Evidence suggests that the primary dose of adenosine should be given as 0.1 mg/kg, administered in an intravenous bolus with a dose up to 6 mg. If the primary dose is insufficient, then the amount is increased by 0.1 mg/kg-0.2 mg/kg to a maximum of 12 mg. Our case demonstrates the response to adenosine after the third dose.
Case presentation: A 12-year-old boy, previously diagnosed with recurrent SVT, presented with a complaint of palpitation for the last 30 minutes. There was no obvious trigger for his palpitation on history and examination. He was conscious, well looking with normal blood pressure, and good perfusion. We started the management in accordance with pediatric advanced life support guidelines, in which we noted a partial response after the administration of the second dose of adenosine. Subsequently, a third dose of adenosine of 0.2 mg/kg was administered, terminating SVT and regaining a normal sinus rhythm in the patient.
Conclusion: After reviewing recent evidence regarding stable SVT management and adenosine side effects, we found that there is no evidence limiting the use of adenosine to only two doses, especially in a case of short or minimal response following the second dose.

Key words: Tachycardia, Supraventricular; Adenosine

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.